I
Intellia Therapeutics
A leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases
At a glance
- Founded
- 2014
- Headquarters
- Cambridge, United States
- Listing
- IPO 2016
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Intellia Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Atlas Venture- NONovartis
Caribou Biosciences- AMAmblyotech
Series B and later4 investors entered at this stage
OrbiMed- UCUniversity of California
- BEBerkeley
Foresite Capital
Source: Dealroom Talent Intelligence.
Alumni founders
Former Intellia Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
LBLocus BiosciencesEst. 2015
Rodolphe Barrangou.United States
GEGentiBioEst. 2020
Adel NadaUnited States
MBMammoth BiosciencesEst. 2017
Jennifer A. DoudnaUnited States
KBKorro BioEst. 2018
Nessan BerminghamUnited StatesGlobal footprint
team presence
across markets
Patents
75 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Intellia Therapeutics was the backer or acquirer, 2021–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Intellia Therapeutics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Intellia Therapeutics deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Intellia Therapeutics's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intellia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intellia Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.